Navigation Links
New TB Vaccine Passes Safety Trial
Date:4/8/2009

Experimental preparation was tested in people with latent infection,,

WEDNESDAY, April 8 (HealthDay News) -- An experimental tuberculosis vaccine called MVA85A proved safe in a small phase I clinical trial.

The study included 12 people with latent tuberculosis infection, which, when re-activated, can cause full-blown TB. It's believed that about a third of the world's population has this latent infection. The participants, who had no other complicating factors, such as hepatitis or HIV, were given the vaccine and then followed for a year.

The researchers concluded that the vaccine was safe, did not produce any immunopathology and was immunogenic in the patients. Some participants had side effects that included fever, headache, fatigue and mild concerns at the site of the vaccination.

The findings appear in the April 15 issue of the American Journal of Respiratory and Critical Care Medicine.

This study could be an important step forward in efforts to introduce a new vaccine to fight TB, according to the researchers, led by Dr. Helen McShane, of the University of Oxford in England. They noted that any new vaccine must be developed with latent TB infection in mind because it might decrease the effectiveness of new vaccines or worsen vaccine-related side effects.

"A more effective vaccine regimen than the currently available bacillus Calmette-Guerin would have a major impact on the global TB burden and, ultimately, will be the most efficient way to control this pandemic," the researchers wrote.

They noted that larger trials of the vaccine "are needed in TB endemic areas to assess the efficacy of this vaccine against the development of TB disease, but these results are very encouraging and justify the further development of this vaccine."

More information

The American Lung Association has more about TB.



-- Robert Preidt



SOURCE: American Thoracic Society, news release, April 7, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay
2. Hard To Treat Diseases (HTDS) Offers Hepatitis A Vaccine in India
3. U.S. Adults Needlessly Vulnerable to Vaccine-Preventable Diseases, According to New Report
4. Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis
5. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
6. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
7. Oral Yogurt Vaccine Could Blunt Ouch Factor
8. HPV Data May Aid Vaccines Effectiveness
9. Saving Vaccines with SensoTech's Breakthrough in Vaccine Temperature Monitoring
10. HARD TO TREAT DISEASES (HTDS) Influenca Vaccine (MEVAC-FLU) Enters Chilean Market
11. TB vaccine developed at McMaster University in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New TB Vaccine Passes Safety Trial
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and ... may have been used to remove decayed dental matter, and that teeth were then ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, ... is a benign bony lump located on the forehead usually attributed to a facial ... sight and pain. Dr. Shah has discovered an approach that is minimally invasive. He ...
(Date:4/21/2017)... ... 2017 , ... Dudnyk has announced the launch of its new brand identity, ... potential of specialty and orphan brands can only be achieved when the needs and ... Effect is at the heart of a true partnership between our agency and our ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
Breaking Medicine Technology: